Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection

Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults

(2018) José A. Suaya et al.   VACCINE

Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions

(2017) Sabelle Jallow et al.   VACCINE

Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions

(2016) Derek Weycker et al.   BMC HEALTH SERVICES RESEARCH

Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States

(2016) Charles Stoecker et al.   JOURNAL OF GENERAL INTERNAL MEDICINE

The cost-effectiveness of pneumococcal vaccination in healthy adults over 50: An exploration of influential factors for Belgium

(2016) Adriaan Blommaert et al.   VACCINE

Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England

(2016) Albert Jan van Hoek et al.   PLoS One

Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study

(2016) Francesca Lombardi et al.   PLoS One

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination

(2015) As’ad E. Bhorat et al.   AIDS

Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain

(2015) Jose Miguel Rodríguez González-Moro et al.   CLINICAL DRUG INVESTIGATION

The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly

(2015) Cornelis H. van Werkhoven et al.   CLINICAL INFECTIOUS DISEASES

Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged ≥2 Years: An Open-Label Study

(2015) Catherine Cordonnier et al.   CLINICAL INFECTIOUS DISEASES

Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands

(2015) Marie-Josée J. Mangen et al.   EUROPEAN RESPIRATORY JOURNAL

Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults

(2015) Marc J.M. Bonten et al.   NEW ENGLAND JOURNAL OF MEDICINE

13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study

(2015) Mariane De Montalembert et al.   PEDIATRIC BLOOD & CANCER

Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan

(2015) Shu-ling Hoshi et al.   PLoS One

Cost-Effectiveness of Pneumococcal Vaccines for Adults in the United States

(2014) Jieling Chen et al.   ADVANCES IN THERAPY

The Intego database: background, methods and basic results of a Flemish general practice-based continuous morbidity registration project

(2014) Carla Truyers et al.   BMC Medical Informatics and Decision Making

Epidemiology and outcome of invasive pneumococcal disease among adults in Belgium, 2009–2011

(2014) J Verhaegen et al.   Eurosurveillance

Cost–effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK

(2014) Yiling Jiang et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults

(2013) Kenneth J. Smith et al.   VACCINE

Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions

(2013) Bo-Hyun Cho et al.   VACCINE

The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England

(2012) Albert Jan van Hoek et al.   JOURNAL OF INFECTION

Aging Population and Future Burden of Pneumococcal Pneumonia in the United States

(2012) Peter C. Wroe et al.   JOURNAL OF INFECTIOUS DISEASES

Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50years

(2012) Derek Weycker et al.   VACCINE

Healthcare utilization and cost of pneumococcal disease in the United States

(2011) Susan S. Huang et al.   VACCINE

Prevalence of high-risk indications for influenza vaccine varies by age, race, and income

(2010) Richard K. Zimmerman et al.   VACCINE

Clinical and economic burden of pneumococcal disease in older US adults

(2010) Derek Weycker et al.   VACCINE

Alternative strategies for adult pneumococcal polysaccharide vaccination: A cost-effectiveness analysis

(2008) Kenneth J. Smith et al.   VACCINE